Group 1: Stock Performance and Rankings - Pediatrix Medical Group, Inc. (MD) has a Zacks Rank 1 and its earnings estimate increased by 15.7% over the last 60 days [1] - Pediatrix's shares gained 35.4% over the last three months, significantly outperforming the S&P 500's 2.9% increase [2] - La-Z-Boy Incorporated (LZB) also holds a Zacks Rank 1 with a 3.2% increase in its earnings estimate over the last 60 days [2] - La-Z-Boy's shares increased by 3% over the last three months, matching the S&P 500's performance [2] - Grupo Cibest S.A. (CIB) has a Zacks Rank 1 and its earnings estimate rose by 8.7% over the last 60 days [3] - Grupo Cibest's shares increased by 22.1% over the last three months, again outperforming the S&P 500 [3] Group 2: Momentum Scores - Pediatrix Medical Group possesses a Momentum Score of A, indicating strong momentum characteristics [2] - La-Z-Boy has a Momentum Score of B, reflecting moderate momentum [2] - Grupo Cibest also holds a Momentum Score of B, suggesting a similar level of momentum as La-Z-Boy [3]

Core Insights - Three stocks are highlighted with a buy rank and strong value characteristics for investors to consider on November 24 Group 1: John B. Sanfilippo & Son, Inc. (JBSS) - The company operates in the tree nuts and peanuts sector and holds a Zacks Rank 1 [1] - The Zacks Consensus Estimate for its current year earnings has increased by 7.8% over the last 60 days [1] - The price-to-earnings ratio (P/E) is 11.84, significantly lower than the industry average of 29.50 [1] - The company has a Value Score of A [1] Group 2: Grupo Cibest S.A. (CIB) - This company provides banking services and products and also holds a Zacks Rank 1 [2] - The Zacks Consensus Estimate for its current year earnings has increased by 8.7% over the last 60 days [2] - The price-to-earnings ratio (P/E) is 7.81, compared to 24.24 for the S&P 500 [2] - The company has a Value Score of B [2] Group 3: Pediatrix Medical Group, Inc. (MD) - The company specializes in newborn care, maternal-fetal medicine, and pediatric subspecialty services, holding a Zacks Rank 1 [3] - The Zacks Consensus Estimate for its current year earnings has increased by 15.7% over the last 60 days [3] - The price-to-earnings ratio (P/E) is 11.19, lower than the S&P 500 average of 24.24 [3] - The company has a Value Score of B [3]

Core Insights - Pediatrix Medical Group, Inc. (MD) has achieved a year-to-date gain of 29.6%, significantly outperforming the industry average decline of 3% [1][8] - The company has a market capitalization of $1.5 billion and a forward P/E ratio of 9.46, which is lower than the industry average of 14.90 [2] - The Zacks Consensus Estimate for Pediatrix Medical's 2025 earnings is $1.78 per share, reflecting a 17.9% year-over-year increase, with revenues estimated at $1.9 billion [3] Financial Performance - In Q2 2025, same-unit revenues rose by 6.4% year-over-year, exceeding the Zacks Consensus Estimate by 5.4% [5] - The company has increased its adjusted EBITDA guidance for 2025 to a range of $245 million to $255 million, up from the previous range of $220 million to $240 million [6] - Total operating expenses decreased by 38.2% year-over-year to $409 million in Q2 2025, with expectations of a nearly 19.2% decline in 2025 [6] Growth Drivers - Growth is driven by strong same-unit revenue gains, improved neonatology patient volumes, stable payor mix, and higher hospital contract administrative fees [4] - The company is focusing on core hospital-based services, particularly in maternal-fetal medicine, neonatology, obstetrics, and pediatric subspecialties [7] Share Repurchase Program - In the first half of 2025, Pediatrix Medical repurchased common shares worth $1.8 million, with an additional $1.1 million remaining authorized for repurchase [7] - A new share repurchase program of $250 million was authorized in August 2025 [7] Debt and Financial Ratios - As of June 30, 2025, the company had a net debt of $607.5 million, significantly higher than its cash balance of $224.7 million [8][9] - The long-term debt-to-capital ratio stands at 41.2%, above the industry average of 39.9% [9]